Category Archives: Sofosbuvir

Healthcare Groups Challenge Patents On Three New Hep-C Drugs In India

Source: Business World The patent challenges could remove barriers to production and distribution of affordable generic versions of direct-acting antiviral medicines, which are currently sold at very high prices Patient and healthcare aid groups, including I-MAK and Delhi Network of … Continue reading

Posted in Evergreening, Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Tagged , , | Leave a comment

Healthcare and patient groups oppose patents on crucial hepatitis C drugs

By Rupali Mukherjee, The Times of India  MUMBAI: Healthcare aid and patient groups have come together in patent courts to fight against “abusive strategies” of Big Pharma, to ensure access to affordable treatment in hepatitis C. The Initiative for Medicines, … Continue reading

Posted in Evergreening, Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Tagged , | Leave a comment

Flawed patents on hepatitis C drugs latest to be challenged in global push for access

Source: MSF Access Campaign New Delhi/New York, 14 February 2017–Five new challenges against patents on crucial new medicines to treat hepatitis C filed in India and Argentina are the latest in a global push to ensure access to affordable treatment. … Continue reading

Posted in Evergreening, Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Tagged , , | Leave a comment

Unavailability of Affordable Hepatitis C Treatments Threatening Malaysian Lives

The World Health Organization (WHO) recently reported that over one million people in low- and middle-income countries have been treated with a revolutionary new cure for hepatitis C since its introduction two years ago.

Posted in Hepatitis C, Sofosbuvir, Uncategorized | 1 Comment

Sofosbuvir patent dispute- Delhi High Court update

A writ petition was filed before the Delhi High Court by I-MAK and DNP+, challenging the grant of patent to costly Hepatitis-C drug, Sofosbuvir. The first hearing for the case was expected take place on 13th September. However, the hearing has … Continue reading

Posted in Hepatitis C, Patent, Sofosbuvir, Uncategorized | Leave a comment

India allows Gilead to patent Hepatitis C drug. Here’s why it is cruel

By Vishakh Unnikrishnan, The CatchNews | May 14, 2016 Landing a blow to efforts to make vital drugs more affordable, the Indian Patent Office has granted the American pharmaceutical company Gilead a patent for sofosbuvir, which is used to treat … Continue reading

Posted in Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Leave a comment

Gilead gets patent for Hepatitis C drug Solvadi

By Vidya Krishnan, The Hindu | May 10, 2016 The decision is a major blow to the access to drug movement, says MSF In direct contradiction to its earlier order, the Controller General of Patents, Designs and Trademark granted American … Continue reading

Posted in Sofosbuvir, Uncategorized | Leave a comment